Trial Profile
A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Interferon gamma-1b (Primary)
- Indications Liposarcoma; Myxoid liposarcoma; Synovial sarcoma
- Focus Biomarker; Pharmacodynamics
- 19 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 08 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2018 Planned number of patients changed from 12 to 10.